𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study

✍ Scribed by Mohs, Richard C.; Shiovitz, Thomas M.; Tariot, Pierre N.; Porsteinsson, Anton P.; Baker, Kurt D.; Feldman, Peter D.

Book ID
123457861
Publisher
American Psychiatric Publishing Inc
Year
2009
Tongue
English
Weight
168 KB
Volume
17
Category
Article
ISSN
1064-7481

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 446 KB πŸ‘ 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

A 6-month, randomized, double-blind, pla
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
✍ D.P. Devanand; Gregory H. Pelton; Karine Cunqueiro; Harold A. Sackeim; Karen Mar πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 215 KB πŸ‘ 2 views

## Abstract ## Objective In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation. ## Methods In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of ha